Heart Failure

Gregg Fonarow, MD; David Aguilar, MD; Rob Mentz, MD; and James Januzzi, MD, discuss the unexpected and exciting use of SGLT-2 inhibitors to treat heart failure.

Rob Mentz, MD, of Duke University Medical School, discusses the CANVAS trial and the pursuit of using SGLT-2 inhibitors to treat heart failure.

Gregg Fonarow, MD, of UCLA, discusses the vital importance of preventing HF in ways outside of just the available treatment options.

Mandeep Mehra, MD, President of the HFSA, discusses one of the HFSA annual meeting's themes: the prophylaxis of heart failure through behavioral and dietary adjustments.

Rob Mentz, MD; David Aguilar, MD; Mandeep Mehra, MD; and Lisa Rathman, MSN, discussed the use of team-based care in heart failure, a condition plagued by comorbidities and often treated by multiple specialists.

David Aguilar, MD, of Baylor College of Medicine, discusses the new responsibilities faced by cardiologists with the emerging onset of dual-indication medicines.

Gregg Fonarow, MD, of UCLA, spoke about the benefits of short-term treatment for keeping HF patients out of hospital, and using hospitalization as a time to learn.

Mandeep Mehra, MD, President of the HFSA, discusses the importance of team-based care between physicians, pharmacists, and nurse practitioners in treating heart failure.

Bertram Pitt, MD, of the University of Michigan School of Medicine, discusses the benefits of subcutaneous furosemide keeping patients from "bouncing back" into the hospital.

Amil Shah, MD, of Harvard Medical School, discusses the utilization of echocardiography - often the first step for the indication of heart failure with preserved ejection fraction - to diagnose patients with the condition and separate them from other morbidities.

James Udelson, MD, the chief of cardiology at Tufts Medical Center, discusses the possibilities offered by the development of subcutaneous furosemide for HF patients in need of diuresis.

No strokes were experienced by the apixaban group, compared to 6 in the warfarin arm of the study.

The novel therapy showed sinus rhythm was present in 75% of patients after 1-year follow-up.

There are currently no known reports of patient harm for the 465,000 implanted devices in question, according to the FDA.

Catheter ablation lowered mortality rates to 13.4% and hospitalization rates to 20.7%, significant decreases compared to the conventional methods.

Despite the results of a large-scale trial, some experts questioned the use of beta-blockers for patients that suffered from heart failure and simultaneous AFib when in the presence of beta-adverse medications, like amiodarone.

A secondary study revealed that the presence of diabetes mellitus in patients with chronic heart failure leads to a higher risk of early death.